Are triplet therapies really living up to their hype as the “standard of care” for multiple myeloma and what else is needed?

Martin SchrederFirst Department of Medicine, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, AustriaView further author information

Stefan KnopDepartment of Internal Medicine II, Division of Hematology and Medical Oncology, University Hospital Wuerzburg, Wuerzburg, GermanyCorrespondence[email protected]
View further author information

Click to increase image sizeClick to decrease image size

Declaration of interest

S Knop has received honoraria from Celgene, Janssen, BMS, Amgen and Takeda as well as travel grants from Celgene and Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Are triplet therapies really living up to their hype as the “standard of care” for multiple myeloma and what else is needed?

Information for

Open access

Opportunities

Help and information

Are triplet therapies really living up to their hype as the “standard of care” for multiple myeloma and what else is needed?

Declaration of interest

Reviewer disclosures

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature